News Conference News ACC 2017 Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them Yael L. Maxwell March 23, 2017
News Conference News ACC 2017 Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS Michael O'Riordan March 19, 2017
News Conference News ACC 2017 ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s Yael L. Maxwell March 17, 2017
News Conference News ACC 2017 SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab Yael L. Maxwell March 17, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2017 More Certainty With Ceramides? New Blood Test May Help ID CAD Patients Early in Disease Yael L. Maxwell March 09, 2017
News Conference News AHA 2016 En mitad de la Marea Creciente de ECVA, los Costes del Tratamiento Deberían hacer que los Legisladores Legislasen en Materia de Prevención Yael L. Maxwell November 29, 2016
News Conference News AHA 2016 Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention Yael L. Maxwell November 29, 2016
News Conference News AHA 2016 My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial Shelley Wood November 28, 2016
News Conference News AHA 2016 ¿Dolor Muscular Secundario a las Estatinas? Según el Análisis GAUSS-3 Podría ser Genético Michael O'Riordan November 22, 2016
News Conference News AHA 2016 Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis Michael O'Riordan November 22, 2016
News Conference News AHA 2016 Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women L.A. McKeown November 17, 2016
News Conference News AHA 2016 PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad Michael O'Riordan November 15, 2016
News Conference News AHA 2016 AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR Shelley Wood November 09, 2016
News Conference News TCT 2016 COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events Michael O'Riordan November 01, 2016